IITRI announces the recent award of three major new programs by the Biomedical Advanced Research and Development Authority (BARDA) valued at more than $4.7 M. The programs are for the development and/or evaluation of cutting edge technologies and agents to control infectious diseases of critical importance to human health.
These new programs include:
- Development and Qualification of Stocks and Assays for Studies with Zika Virus
- Development of a Novel Model to Evaluate Vaccine Efficacy against Influenza
- Efficacy Studies of Monoclonal Antibodies against Ebola Virus (joint program with Texas Biomedical Research Institute)
Congratulations to Robert Baker, David Boltz, and the entire IITRI team for winning these programs.